email article
Prostate MRI followed by selective biopsy detected as many clinically significant cancers as standard ultrasound-guided systematic biopsy and detected 50% fewer low-risk cancers, a large randomized trial showed.
Targeted biopsy with multiparametric MRI identified grade group (GG) ≥2 tumors in 35% of men as compared with 30% for systematic biopsy with transrectal ultrasound (TRUS) guidance. The proportion of GG1 tumors decreased from 22% with TRUS biopsy (Bx) to 10% with targeted MRI-guided biopsy. Almost 40% of men randomized to the MRI group had negative imaging results, allowing them to avoid biopsy altogether.
Men who had MRI-guided prostate biopsy also had fewer adverse events (AEs), Laurence Klotz, MD, of the Sunnybrook Health Sciences Center in Toronto, and coauthors reported in